Form 4: CYTOKINETICS CCO Sells Shares for Tax Obligations

Cytokinetics' Chief Commercial Officer, Andrew Callos, sold 1,368 shares of common stock to cover tax withholding obligations related to vested performance stock units.

Summary

• Andrew Callos, Executive Vice President and Chief Commercial Officer of CYTOKINETICS INC (CYTK), reported a transaction involving the company's common stock.
• The transaction, dated December 3, 2025, was a 'sell to cover' for tax withholding purposes.
• A total of 1,368 shares of common stock were disposed of at a price of $65.02 per share.
• This sale was related to the vesting of Performance Stock Units that were granted on March 14, 2024, and earned on December 2, 2024.
• Following this transaction, Andrew Callos beneficially owns 50,660 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax withholding purposes upon the vesting of performance stock units, indicating a non-discretionary sale rather than a change in investment sentiment. This is a neutral event.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal as this is a small, non-discretionary sale for tax purposes, not indicative of a change in the executive's view of the company's prospects.

Key Dates

Recommendation

The transaction reported is a standard 'sell to cover' for tax withholding purposes following the vesting of performance stock units. This is a non-discretionary sale and does not reflect a change in the executive's confidence in the company or its future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

CYTOKINETICS, CYTK, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Executive Compensation, Andrew Callos, Rule 10b5-1